

Bertrand Rochat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/880261/publications.pdf>

Version: 2024-02-01

30
papers

1,122
citations

394421

19
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

1701
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust and sensitive peptidomics workflow for plasma based on specific extraction, lipid removal, capillary LC setup and multinozzle ESI emitter. <i>Talanta</i> , 2021, 223, 121617.	5.5	2
2	Quantitative and Qualitative LC-High-Resolution MS: The Technological and Biological Reasons for a Shift of Paradigm. , 2019, .		7
3	LC-HRMS Metabolomics for Untargeted Diagnostic Screening in Clinical Laboratories: A Feasibility Study. <i>Metabolites</i> , 2018, 8, 39.	2.9	11
4	Fully-automated systems and the need for global approaches should exhort clinical labs to reinvent routine MS analysis?. <i>Bioanalysis</i> , 2018, 10, 1129-1141.	1.5	4
5	Proposed Confidence Scale and ID Score in the Identification of Known-Unknown Compounds Using High Resolution MS Data. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 709-723.	2.8	62
6	Quantitative performance of a quadrupole-orbitrap-MS in targeted LC-MS determinations of small molecules. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 124, 48-56.	2.8	61
7	Validation of the Mass-Extraction-Window for Quantitative Methods Using Liquid Chromatography High Resolution Mass Spectrometry. <i>Analytical Chemistry</i> , 2016, 88, 3264-3271.	6.5	46
8	From targeted quantification to untargeted metabolomics: Why LC-high-resolution-MS will become a key instrument in clinical labs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 151-164.	11.4	78
9	Is there a future for metabotyping in clinical laboratories?. <i>Bioanalysis</i> , 2015, 7, 5-8.	1.5	8
10	Improved Investigations in Drug Safety by More In-Depth Individual Pharmacokinetics Using High-Resolution Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 141-146.	2.0	2
11	Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance. <i>PLoS ONE</i> , 2014, 9, e95532.	2.5	26
12	SIMPLE MEASUREMENT OF TESTOSTERONE IN MALE SALIVA SAMPLES USING DISPERSIVE LIQUID-LIQUID MICROEXTRACTION FOLLOWED BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY DETECTION. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2014, 37, 1278-1286.	1.0	6
13	Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 2627-2640.	3.7	34
14	A Close Look at the Fate of Compounds we are Exposed to. <i>Chimia</i> , 2014, 68, 818-818.	0.6	1
15	Analysis and quantification of vitamin D metabolites in serum by ultra-performance liquid chromatography coupled to tandem mass spectrometry and high-resolution mass spectrometry a method comparison and validation. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 200-206.	1.5	75
16	Metabotype analysis for personalized biology: a new bioanalytical territory for high-resolution MS. <i>Bioanalysis</i> , 2013, 5, 1149-1152.	1.5	6
17	Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform. <i>Bioanalysis</i> , 2013, 5, 2509-2520.	1.5	31
18	Quantitative/qualitative analysis using LC-HRMS: the fundamental step forward for clinical laboratories and clinical practice. <i>Bioanalysis</i> , 2012, 4, 1709-1711.	1.5	31

#	ARTICLE	IF	CITATIONS
19	The future key role of LCâ€‘high-resolution-MS analyses in clinical laboratories: a focus on quantification. <i>Bioanalysis</i> , 2012, 4, 2939-2958.	1.5	48
20	Comparison between a highâ€‘resolution singleâ€‘stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. <i>Rapid Communications in Mass Spectrometry</i> , 2012, 26, 499-509.	1.5	124
21	Generic approach for the sensitive absolute quantification of large undigested peptides in plasma using a particular liquid chromatographyâ€‘mass spectrometry setup. <i>Journal of Chromatography A</i> , 2011, 1218, 8536-8543.	3.7	14
22	Comparison between a linear ion trap and a triple quadrupole MS in the sensitive detection of large peptides at femtomole amounts on column. <i>Journal of Separation Science</i> , 2010, 33, 2478-2488.	2.5	21
23	Ultra-Performance Liquid Chromatography Mass Spectrometry and Sensitive Bioassay Methods for Quantification of Posaconazole Plasma Concentrations after Oral Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5074-5081.	3.2	21
24	Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- <i>N</i>-Oxide, Anidulafungin, and Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5303-5315.	3.2	108
25	Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatographyâ€‘mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008, 43, 736-752.	1.6	52
26	<i>In vitro</i> biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 103-118.	1.9	26
27	Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. <i>Journal of Mass Spectrometry</i> , 2007, 42, 440-449.	1.6	20
28	Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatographyâ€‘triple-quadrupole and linear ion trap mass spectrometers. <i>Journal of Mass Spectrometry</i> , 2006, 41, 390-404.	1.6	49
29	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	1.0	28
30	Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance. <i>Clinical Pharmacokinetics</i> , 2005, 44, 349-366.	3.5	120